Judy S. Wang

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i>

Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer et al. · Clinical Cancer Research · 2021 · 147 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

María Vieito, Víctor Moreno, Anna Spreafico et al. · Clinical Cancer Research · 2023 · 77 citations

Medicine, Pharmacokinetics, Pharmacology +17

Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER).

Gerald S. Falchook, Antoni Ribas, Diwakar Davar et al. · Journal of Clinical Oncology · 2022 · 75 citations

Pharmacy, Immunology, Pharmacology +17

Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Devalingam Mahalingam, Judy S. Wang, Erika Hamilton et al. · Clinical Cancer Research · 2019 · 72 citations

Medicine, Pharmacokinetics, Pharmacology +14

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

Andrew J. Armstrong, Ravit Geva, Hyun Cheol Chung et al. · Investigational New Drugs · 2024 · 62 citations · Full text

Medicine, Oncology, Pharmacology +17